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1. Introduction
Autism Spectrum Disorder (ASD), also currently known as autism, refers to a group of complex
behavioral disorders of varying severity, characterized by manifestations noted in early
childhood, usually before the age of three and defined as impaired social communication and
presence of restricted interests and repetitive behaviors, compromising the entire life of the
individual (DSM-5). The etiology is very complex and heterogeneous, with numerous causes
described, and includes genetic, epigenetic, or environmental factors in isolation or associated.
It aggregates in families with the heritability being estimated at 0.50, but the individual risk
and to what extent this is caused by genetic factors or environmental factors remains unre‐
solved. These factors probably interact at least in the majority of cases, and thus the assessment
of individuals and genetic counseling is further complicated [124].
Valuable information is been gained through the identification of candidate genes, though
case-control and association studies and more recently by comparative genomic hybridization
and whole exome and genome sequencing. In the epigenetic area, mechanisms such as
genomic imprinting, epimutations and methylation have been identified [133]. Copy number
variations (CNVs) have gained prominence on the stage of the discovery of the causes of
autism. The de novo CNVs have been reported in 7% of simplex families and ~2% in multiplex
families. Moreover, hypomorphic alterations in some genes suggest oligogenic inheritance.
Recently, discoveries employing large-scale whole exome sequencing (WES) showed that one
gene alone is not able to confer significant risk for autism. Instead, the most probable hypoth‐
esis is the contribution of several risk variants that are scattered in hundreds of genes. There
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
are approximately 4,000 genes involved in molecular pathways, gene regulation and functional
domains that may contribute to neurodevelopmental disorders. It is noteworthy that the same
genes can cause different disorders leading to an etiologic overlap [35].
One other issue that has emerged recently is that a significant number of synaptic proteins
directly or indirectly affect the structure and function of neurons, dendrites and synapses.
Subtle changes in the dendritic and synaptic structures can lead to huge changes in information
processing. Dendritic branches and spines are essential for the formation and plasticity of
neuronal circuits but are interrupted in many neurologic disorders, such as autism. In many
cases the same mutations are observed in unaffected relatives. This suggests the existence of
a compensatory mechanism or other genetic or non-genetic causes [140].
New findings on the genetic etiology of autism have pointed to the participation of regulatory
regions of transcription factors, the microRNAs (miRNAs), a class of noncoding RNAs of ~22
nucleotides that suppress translation by pairing with miRNA recognition elements present in
the 3'untranslated region (3'UTR) of target mRNAs. Candidate genes and sites of miRNA
targets have been identified from these. It is known that the expression of many genes involved
in autism is regulated by miRNAs. Single nucleotide polymorphisms (SNPs) have been
described as modulators or creators of new recognition elements of miRNAs. Therefore, there
is a hypothesis that SNPs disrupting the interaction between miRNA and genes can lead to
the aberrant expressions of genes implicated in autism, resulting in susceptibility to disease or
pathogenesis in at least one subpopulation of affected individuals [149].
Although the involvement of genetic abnormalities in autism is well accepted, recent studies
have indicated that there is a similar contribution of environmental factors. However, studies
related to the environment, especially those regarding toxic products, have not been system‐
atically reviewed yet, as many studies have limitations, including a lack of reproducibility,
small sample size, retrospective design, bias between cases and controls and non-use of an
appropriate autism diagnostic tool. Thus, in general, there is a potential involvement of some
toxic products in complex genetic-environmental interactions which act synergistically or in
parallel on the brain in a way that increases the likelihood of developing autism.
Moreover, although some studies suggest that autistic characteristics are due to central
nervous system (CNS) dysfunction, there is evidence of autism-related abnormalities that are
not related to the CNS, at least in some individuals. Hence, the metabolic system, immune
system dysregulation and oxidative stress have also been implicated in the etiology [107].
Furthermore, other new lines of research also point to the importance of the so-called "brain-
gut axis" revealing the central role of the intestinal microbiota in postnatal development and
maturation of the immune and endocrine systems that, in turn, control CNS signaling, brain
function and behavior [151]. But studies on this line must be carefully analyzed.
The low recurrence related to any one cause is one of the most intriguing aspects of the etiology,
as is the difference in the proportion of affected between the genders, because men are four
times more affected by ASD than women (CDC, 2014). Additionally, there is an association
between increased paternal age and risk for ASD. This finding may indicate that de novo
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mutations, which are more common in older men, may play a smaller role in the incidence of
autism than the familial genetic load [73].
Investigating and understanding the etiology of autism is extremely important for families
because it allows a determination of the recurrence risk, the possibility of detecting other
associated medical problems, an assessment of the molecular nature and cellular pathophysi‐
ology, and potential therapeutic approaches. In this context, the aim of this chapter is to
provide the reader with an overview of these possible causes and others that may contribute
to autistic behavior.
2. Common chromosomal alterations: 15q11-q13, 16p11.2 and 22q11.2
In addition to well-established genic syndromes, a lot of cases of ASD present with numerical
or structural chromosomal alterations visible by conventional cytogenetic techniques [164].
Due to the high number of cases and the type and location of the genes described, the associ‐
ation of some chromosomal regions is well established in autism including: 1q21, 2q37, 7q11.23,
15q11-13, 16p11.2, 17p11.2, 22q11.2 and 22q13. Rearrangements involving these regions are
detected by GTG banding however more sophisticated molecular techniques are recommend‐
ed. High-resolution whole-genome analysis with array-based technologies have revealed
genomic imbalances in at least 10% of cases (Depine et al., 2009).
Chromosome 15 is reportedly the most common site of autosomal abnormalities in autism
with the duplication of 15q11-q13 being the most frequently reported alteration. This region
contains at least 30 genes, several of which have been associated to ASD, neurobehavioral
disorders, cognitive deficits, hypotonia, language delay and seizures [141, 154].This region,
known for its genetic instability, contains many low copy repeats and segmental duplications.
It is known as a critical region for Prader-Willi/Angelman syndrome and has a complex pattern
of paternal and maternal imprinting; it contains at least five paternally expressed genes
(MKRN3, MAGEL2, NDN, C15orf2, snoRNAs and SNRPN-SNURF) and two maternally
expressed genes (UBE3A and ATP10A). Furthermore, epigenetic factors regulating 15q11-13
have been implicated in the presence of autism [6].
The phenotype involving recurrent ∼600 kb microdeletions and microduplications in the
16p11.2 region is characterized by a spectrum of neurodevelopmental impairments including
developmental delay and intellectual disability, epilepsy, autism and other psychiatric
disorders which are all subject to incomplete penetrance and variable expressivity. This
deletion is observed in ~0.5% of autism patients, making this the second most common
abnormality in this disorder [48, 156]. Losses in candidate genes in this region, such as ALDOA,
DOC2A, HIRIP3, MAPK3, MAZ, PPP4C, SEZ6L2, and TAOK2, seem to contribute to the ASD
phenotype (Kumar et al., 2009).
The 22q11.2 deletion is one of the most commonly known interstitial deletions identified in
humans, and with a frequency of around 1:4,000 live births in the general population, it is
related to DiGeorge Sequence/Velocardiofacial syndrome [98, 132]. Recent studies suggest that
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the high prevalence of autistic behaviors in children with 22q11.2 deletions should not be
viewed only as ASD but as prodromal symptoms preceding the onset of schizophrenia [9, 132,
153]. Individuals with hemizygosity of the 22q11.2 deletion represent genetically identifiable
cases of ASD. However, the 22q11.2 gene(s) responsible for ASD have not been identified yet.
Tbx1 is one of the candidate genes, possibly through its role in diverse cell types, including
prenatally and postnatally generated neurons.
Several large chromosomal microarray studies have reported the prevalence of CNV variants
in people with particular features (e.g., autism, schizophrenia, and epilepsy) but few studies
have investigated the prevalence in the general population. In a screening of 6,813 consecutive
cord blood samples from a predominantly French–Canadian population to assess genomic
CNVs, 23 children were identified with alterations in 15q11-q13, 16p11.2 or 22q11.2. Longitu‐
dinal follow-up studies are needed to determine the clinical consequences of CNVs identified
at birth [146]. Anyway, considering the important implications for genetic counseling, these
regions must be evaluated in ASD patients.
3. Copy number variations (CNVs)
Dysregulation of gene expression of several genes/loci converging on the same networks
(overlay) and/or combinatorial effects of different deleterious genetic variations appear to
exceed a threshold and result in the autistic phenotype. In support of these ideas, strategies
based on bioinformatics have identified many candidate genes, showing that ASD can be
triggered by different types of genetic variations in many different genes, a phenomenon
known as non-allelic genetic heterogeneity [74, 138, 105]. This model is more accepted;
combines both common and rare variations posing risk for ASD, particularly those involving
synaptic genes and genes involved in neurogenesis [138]. Thus it is assumed that people with
ASD have a set of genetic variants that predispose them to abnormal development of brain
structures involved in processing social information (the "social brain"). But it is known that
there is no common pathophysiology in ASD. This may result from mutations in many
different genes involved in different functions [138]. The kinds of variants that incline to autism
and can involve several genes at the same time are the CNVs.
CNVs are microduplications or microdeletions resulting from insertions, deletions or trans‐
locations in the human genome that are observed in the general population and commonly
found in genic regions in individuals with neuropsychiatric disorders. They can be inherited
or de novo, frequent or rare with a frequency of less than 1% of the population. A substantial
portion of autism cases appears to result from rare CNVs with variations larger than 100kb;
they are more common in individuals with ASD than in the general population [33, 83, 118].
De novo CNVs have been reported in 5-10% of cases of idiopathic ASD. Many studies have
revealed that some CNVs occur at significantly higher frequencies than others and some are
exclusively observed subjects and not found in normal controls. This has allowed the identi‐
fication of new candidate genes which have not yet been described in the Autism Chromosome
Rearrangement Database, such as GABRA5, GABRA3, GABRG3, UBE3A, E2F1, PLCB1, PMP22,
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AADAT, MAPK3, NRXN1, NRG3, DPP10, UQCRC2, USH2A, NECAB3, CNTN4, LINGO2,
IL1RAPL1, STXBP5, DOC2A, SNRPN, E2F1, AADAT, NECAB3, GPHN, dlg2, HPCAL1, BDNF-
OS and IL1RAPL1, (http://projects.tcag.ca/autism/). The new risk loci for ASD have functions
that suggest an important role in the function and architecture of the brain; one CNV could
interfere with normal biochemical pathways and predispose to the disorder [27, 46, 95). CNVs
associated with ASD and schizophrenia are also associated with cognitive problems in control
subjects showing a probable variable expressivity of these changes [134].
Although structural variations, such as CNVs, play an important etiologic role in the devel‐
opment of ASD as has been proposed by several authors since 2006, most of the results of
different studies are not considered in the clinical evaluation of children with ASD, probably
due to the rarity of individual variants, the lack of coverage of probes in clinical microarrays,
the lack of reproducibility of studies that present different findings and the difficulty to
understand the biology corresponding to some variants even when they are significantly
associated with ASD. Nevertheless, clinical guidelines suggest that microarray-based tests are
the first step in the genetic analysis of children with ASD (128, 68]; however this is not feasible
in most cases of low-income countries due to the high cost of these tests.
4. Cellular adhesion molecules (CAMs)
While the majority of genetic mutations currently linked to autism are rare variants that change
the protein-coding sequence of synaptic candidate genes, regulatory polymorphisms affecting
constitutive and alternative splicing have emerged as risk factors in other diseases, accounting
for an estimated 40-60% of general disease risk [131].
Neurons communicate via synapses, mainly mediated by precisely controlled intercellular
interactions. Interactions between presynaptic and postsynaptic cellular adhesion molecules
(CAMs) drive synapse maturation during development. CAMs provide "bridges", that is, cell-
to-cell connectivity between pre and postsynaptic sites. These transsynaptic interactions are
regulated by alternative splicing of CAMs RNAs, which ultimately determines neurotrans‐
mitter phenotype. Failure to generate the appropriate CAMs can result in loss of activity-
dependent neuronal plasticity, and risk for developmental disorders, including autism.
However, it remains unclear as to how many and which proteins are involved in the synap‐
togenesis process [161]. The postsynaptic proteome of excitatory synapses of a mammalian
brain contains over 1,000 proteins, indicating complex protein-protein interactions that occur
both within and between synapses [15, 30, 32, 47].
Typically, CAMs are located at the center of synapse and contain three domains: an intracel‐
lular domain that interacts with the intracellular scaffolding protein, a transmembrane domain
and an extracellular domain which interacts with other CAMs [101]. Intercellular interactions
in synapses mediated by protein-protein CAMs are involved in recognition and alignment of
pre and postsynaptic sites, transsynaptic signaling, the exact location of neurotransmitter
receptors and release of synaptic vesicles. There are several families of CAMs that have already
been recognized, including neurexins (Nrxs) and neuroligins (NLS), neuronal transmembrane
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proteins rich in leucine (LRRTMs), N-cadherin/β-catenin, ephrins and Eph, SynCAM receptors
and integrins [161].
The Nrxs and NLS contain an extracellular domain that participates in the pre and postsynaptic
interaction and an intracellular domain that is involved in multiple functional interactions and
regulatory processes. They interact with high affinity via their extracellular regions [135, 136].
Nrxs create extracellular protein-protein interactions with the intracellular signaling cascade.
NLS binds to areas of postsynaptic density (PSD), proteins which are supported by glutama‐
tergic synapses. In postsynaptic sites, the NLS/Nrxs interactions cause an increase in the PSD
agglomeration recruitment of postsynaptic N-methyl-D-aspartate (NMDA) and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA). Thus, the binding of Nrxs and NLS
helps to align presynaptic and postsynaptic receptor release (Budreck et al., 2013; Mondin,
Tessier, Thoumine, 2013).
LRRTM proteins are a group of type I transmembrane proteins containing extracellular leucine-
rich repeats and a short cytoplasmic tail. They play a key role in the development and matura‐
tion of synapses, but are also directly involved in synaptic transmission and more complex
behavior [87]. Contactins (CNTNs) provide a set of glycan phosphatidyl-inositol (GPI) Ig-
CAM links containing six N-terminal Ig-like domains and four Fibronectin Type III domains.
CNTNs play an important role in the formation of axon connections in the developing nervous
system. For example, Cntn-1 and Cntn-2 are involved in axon growth and guidance, and Cntn-6
is expressed in the presynaptic region in the developing nervous system [169].
As most neurological diseases originate as a dysfunction of neural circuits whose function is
highly dependent on the accuracy of cell-cell adhesions, there is increasing evidence connect‐
ing several neurological disorders with mutations or altered expressions of CAMs. For
example, mutations in the NLS and Nrxs genes are found in patients with autism (Sudhof,
2008). Therefore, research on the role of CAMs will help provide a better understanding of the
underlying mechanisms of pathogenic neurological disorders (Frei & Stoeckli, 2013).
5. Synaptic vesicles
Alterations in neurotransmission and its components, such as synaptic vesicles seem to be one
of the keys in neurological disorders. Abnormalities in synaptic vesicle endocytosis and
recycling may contribute with this type of disorder. Exoendocytic cycling of synaptic vesicles,
which are organelles of 40 nm in diameter, is involved in neurotransmitter release. Hundreds
of synaptic vesicles, filled with neurotransmitters are found in each presynaptic nerve
terminal. When presynaptic plasma membranes depolarize, Ca2þ-channels open and calcium
flows into the nerve terminal, triggering the exocytosis of synaptic vesicles and releasing their
neurotransmitters into the synaptic cleft. Calcium binds to synaptotagmin, and after exocyto‐
sis, vesicles are re-endocytosed, recycled, and refilled with neurotransmitters. Recycling can
occur by multiple parallel pathways, either by fast recycling via local reuse of vesicles, or by
slower recycling through an intermediate endosomal (Sudhof & Ryzo, 2014). Also, a critical
step in presynaptic differentiation is the clustering of synaptic vesicles near neurotransmitter
release sites, the active zone, where vesicle fusion and exocytosis of neurotransmitters occur.
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Synaptic vesicles at presynaptic terminals store neurotransmitters from presynaptic neurons
such as gamma-aminobutyric acid (GABA) and glutamate [133].
Many presynaptic molecules are involved in the regulation of synaptic vesicle release,
including CAMs. The family of adaptor protein (AP) complexes, AP-1, AP-2, AP-3 and AP-4
mediates various types of vesicle formation and selection of cargo molecules for inclusion in
these vesicles. The synaptic vesicle process involves AP-2/clathrin-mediated endocytosis [133].
The structural composition of synapses may be altered by mutations or deletions in other
scaffold proteins, such as those of the Shank family, neurexin and NLS. These changes may
result in an altered number of receptors such as mGluR receptors or changes in the composition
of NMDA and AMPA, and affect component signaling in PSD. Dysregulation in the synapse
morphology induced by structural alterations and disturbed signaling might converge and
lead to disrupted long-term potentiation (LTP) formation and plasticity, and a specific decrease
in excitatory signaling by various genetic mutations, environmental factors, or immune system
alterations, which would lead to an imbalance in inhibition and excitation as a likely cause of
autism [26].
The main excitatory neurotransmitter in the brain, glutamate, modulates the neuronal
formation and synaptic strength in the early phases of development due to its role in neuronal
plasticity and cognitive functioning [88]. Glutamate receptors are diffused throughout the
brain, in the cerebellum and hippocampus, regions implicated in ASD pathogenesis [25].
Genetic alterations in glutamate signaling have been found in association with ASD through
candidate gene screening and genetic association studies and an imbalance in excitation and
inhibition with glutamate signaling is proposed as a mechanism involved in ASD during the
early development stages, between one and three years of age [112].
There are two types of glutamate receptors, metabotropic and ionotropic. Metabotropic
glutamate receptors (mGluR) are G-protein coupled receptors involved in intracellular signal
transduction and can be divided into three groups: Groups I (mGluR1 and mGluR5), II
(mGluR2 and mGluR3) and III (mGluR4, mGluR6, mGluR7 and mGluR8). Group I receptors
activate phospholipase C. Groups II and III are negatively linked to cyclic adenosine 3′,5′-
monophosphate (AMP) production, but they differ in agonist selectivity. Two Group III
receptors, mGluR7 and mGluR8, are located within the presynaptic grid, whereas mGluR3
and mGluR2 are located on the preterminal axons. Ionotropic glutamate receptors form ligand-
gated ion channels (LGICs) and are labeled according to their prototypical agonists: NMDA,
AMPA and kainate [25].
Some studies have focused on the endocytosis, docking, priming, fusion and recycling
processes that may play a role in intellectual disability and ASD, but the functions of several
vesicle components remain unidentified and more studies are needed to understand these
processes [133].
6. Cytoskeletal dynamics
The cytoskeleton forms the backbone of neuronal architecture and is essential for axon growth
and synapse formation. The microtubule cytoskeleton has an active role during different
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phases of neuronal polarization; microtubules and their stability determine axon formation,
they maintain the identity of axons and they regulate the dynamics of dendritic spines. Once
the synapses have been formed, the neuronal cytoskeleton supports maturation and mainte‐
nance, and so the synaptic cytoskeleton is essential for the stabilization and remodeling of
synaptic connections [40]. Actin filaments are the predominant component of the cytoskeleton
in dendritic spines [20]. Changes in these key molecules mediating that bind to actin and
members of the Rho family of small GTPases, such as RhoA, Rac and Cdc42 can disrupt this
process [69]. These proteins play important roles in synaptic functions, dendritic branching,
the formation and maintenance of dendritic spines and the growth and differentiation of
neurites [133]. Their genes include OPHN1, MEGAP, OCRL1, ARHGEF6, ARHGEF9, FGD1,
LIMK1, PAK3, and IQSEC2 [133].
It is known that genetic alterations in the pathways controlling local protein synthesis in
neurons contribute to diverse intellectual disabilities and ASD. A set of cytoskeletal proteins
has been reported as mutated in these individuals. The resulting disorders are called synap‐
topathies with dysgenesis of dendritic spines being a recurrent anatomical feature. These
include factors that regulate the dynamics of the actin cytoskeleton, such as GAPs and
guanosine factors (Ba; van der Raadt, Nadif Kasri 2013). Mutations in the tumor suppressor
genes, TSC1 and TSC2, are also connected to the ASD mutant proteins that seem to disturb the
dynamics of the cytoskeleton and the structure of dendritic spines [61]. Moreover, the
microtubule-associated protein, KATNAL2, has emerged as a risk factor for ASD [105]. But the
best example of dendritic spine defects is Fragile X syndrome. This disease results from a loss
of function of the RNA-binding protein, the fragile X mental retardation protein (FMRP), which
regulates dendritic targeting of mRNAs and controls protein synthesis and mRNA decay in
neuronal soma and at synapses. High-throughput screenings have revealed that a wide array
of neuronal mRNAs is targeted by FMRP, suggesting that simultaneous dysregulation of many
proteins contributes to the syndrome, including cytoplasmic FMRP-interacting protein 1
(CYFIP1) [38].
New research has revealed many interactions associated with brain disorders, opening up new
perspectives to define regulatory pathways shared by neurological disabilities characterized
by dendritic spine dysmorphogenesis.
7. Translational regulation and the process of ubiquitination
It has been seen that many synaptic proteins are critical to the formation and maintenance of
proper synaptic function. The expression level of many of these proteins may be tightly
controlled by the balance between translation and turnover. The growing number of devel‐
opmental cognitive diseases, whose underlying cause is a defect in the regulation of either
translation or turnover, suggests that the equilibrium between these opposing processes is a
sensitive point in establishing normal cognition and behavior [36].
Ubiquitination, the covalent attachment of ubiquitin to a target protein, regulates most cellular
processes and is involved in several neurological disorders. Many genes in the ubiquitin
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pathway and neuronal proteins that are targeted by the ubiquitin-proteasome system have
been linked to cognitive deficits [57, 82].
Studies have highlighted an important role for protein degradation by the ubiquitin protea‐
some system (UPS) in synaptic plasticity [126, 91]. These observations suggest that changes in
synaptic transmission involve extensive regulation of the synaptic proteome. The synaptic
proteome is also affected by nonsense-mediated mRNA decay (NMD) that provides a quality
control linked to translation. NMD has a role in degradation of aberrant mRNAs with a
premature termination codon and the regulation of the transcriptome [109]. CNVs and
mutations in several genes associated to NMD such as UPF3B, UPF3A, SMG6, EIF4A3,
RNPS1 and RBM8A have been identified as probable causes or predisposing factors for
neurodevelopmental disorders such as autism [5, 76, 108].
UPS consists of a group of enzymes, an ubiquitin activating enzyme (E1), an ubiquitin
conjugating enzyme (E2) and an ubiquitin ligase (E3), which are associated with ubiquitin
ligases and proteasomes to mediate protein degradation. The ubiquitinated target protein is
subsequently shuttled to a protease complex known as the 26S proteasome and subjected to
degradative proteolysis. They also play a role in the regulation of cell signaling and cell cycle
progression, and are associated with cytoskeletal elements. Thus, posttranslational ubiquiti‐
nation modifies protein function and triggers the subsequent degradation of ubiquitinated
proteins by the 26S proteasome. Several components of the UPS are required for proper brain
development, axon guidance, and the development and plasticity of synapses. It has been
shown that protein degradation via the UPS controls the appropriate synaptic balance,
maintaining optimum levels of the protein, thereby promoting functional balance [23].
Several studies have shown a crucial role of UPS in neuronal transmission. For example,
mutations in UBE3A have been associated with ASD. UBE3A encodes an ubiquitin E3 ligase
that contains a domain that catalyzes the ubiquitination of target proteins. A reduction in
density results in defects in synaptic plasticity [57]. UBE3A regulates the development of
excitatory synapses by controlling the degradation of activity-regulated cytoskeletal protein
(Arc or Arg3.1). Arc is critical for long-term memory formation and essentially every form of
plasticity, including LTP, long-term depression (LTD), and homeostatic scaling (Greer et al.,
2010). It has been shown that UBE3A-deficient mice, express high levels of Arc in response to
synaptic activity, which coincides with severely impaired hippocampal LTP [78, 133]. Also,
Arc regulates the ionotropic glutamate receptor (iGluRs) expression and trafficking. Findings
from various experimental systems implicate iGluR dysfunction in ASD [148].
8. miRNAs
As previously reported, CNVs are recognized as important genetic factors in ASD, with a high
prevalence of de novo CNVs in sporadic and familial cases compared with control subjects.
However, studies conducted so far have highlighted a pathogenic role of CNVs in terms of
changes in dosage of encoding protein genes without bearing in mind the potential involve‐
ment of non-encoded RNAs, particularly miRNAs, even with the inherent difficulties of this
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type of study [120, 150]. Generally these two themes (CNV and miRNAs) are investigated
separately.
A few studies have investigated the transcriptome in ASD samples of postmortem brains and
some of them used mRNA from peripheral blood of patients [1, 54, 71, 110]. More recently,
disruption of miRNA expression has been repeatedly reported in microarray studies and it is
believed to be linked to the pathogenesis of autism (Sarachana et al., 2010; [28, 55]. However,
lymphoblastoid cells are not representative of neural tissue and very few miRNAs exhibit
consistent deregulation between studies.
According to [93], miRNA loci are underrepresented in highly polymorphic and well-
validated CNV regions. One study investigated the pathogenic role of miRNAs in autism by
checking associations with de novo CNVs. Twenty-four miRNA genes likely to play a patho‐
genic role in autism were identified on chromosomes 1, 2 and 22. Two, mir-HSA-4436b-1 and
4436b-HSA-mir-2, appear to be strong candidates. Unfortunately, the targets of these miRNAs
were not identified [94]. The difference in penetrance of the deleted/duplicated genes may be
explained by a variety of factors including: (i) pre-natal exposure to environmental risk factors;
(ii) the presence/absence of functional SNPs in genes that encode proteins related to suscept‐
ibility for autism; (iii) epistasis; (iv) epigenetic factors and (v) the number and type of genes
encoding proteins co-existing in different CNVs and overlapping in the same miRNA.
The HEY1, SOX9, miR-486 and miR-181b are some candidate genes. All of these are involved
in the development and function of the nervous system, and some, such as HEY1, are involved
in Notch signaling networks [55]. However, a systematic analysis of CNV-miRNAs based on
their interactions with target genes identified other miRNAs such as hsa-miR-590-3p, hsa-
miR-944, miR-HSA-570, hsa-miR-34a, hsa-miR-124, hsa-miR-548f, hsa-miR-429, miR-
HSA-200b, hsa-miR-195 and miR-497-HSA. Moreover, the miRNAs related with CNVs can
explain the difference in levels of the important genes that are controlled by them. These CNV-
miRNAs can also harm the overall biogenesis and processing of all miRNAs by targeting key
molecules in the miRNA pathway [150].
On the other hand, dysfunction of neuronal miRNAs can result in a number of neuropatho‐
logical conditions. It has been reported that neural miRNAs and their target mRNAs are co-
expressed, suggesting their participation in feedback mechanisms to connect the
transcriptional activation with the control of local dendritic protein synthesis [145]. Interest‐
ingly, the functions attributed to miRNAs overlap with growth abnormalities, delays and the
disruption of neuronal maturation observed in the brains of autistic individuals. Aberrations
in the translational control of multiple mRNAs mediated by targets of each miRNA may lead
to the difference in phenotypes observed in ASD. Moreover, multiple miRNAs may target the
same mRNA leading to phenotypes resulting from the converging of several loci in CNVs.
Thus, a change in expression or level of miRNA will affect the expression of target genes and
might have a pleiotropic effect that would produce a more severe autistic phenotype. However,
one can not underestimate the clinical relevance of the deregulation of a single or a subset of
CNV-miRNAs. Based on this, it is clear that the characterization of this relationship may
illustrate the complexity of the underlying neuronal development, function and dysfunction
that will eventually help in the understanding and treatment of autism [150].
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9. Chromatin remodeling
Chromatin is defined simply and collectively as genomic DNA associated to proteins within
the nucleus. There is a vast assortment of chromatin factors dedicated to the DNA packaging
and the enzymatic functions involved in changing chromatin states. Nucleosomes are the
primary unit of chromatin organization with a histone core (H2A/B, H3, and H4) and linking
subunit H1. They keep DNA condensed and regulated by only releasing genes into the open
conformation when their accessibility is needed (Lasalle, 2014). Interestingly, disruptions in
chromatin regulator genes are frequently the cause of neurodevelopmental and neuropsychi‐
atric disorders. Chromatin regulators are widely expressed in the brain, yet symptoms suggest
that specific circuits are altered when they mutate [143]
Chromatin regulator genes are also altered by de novo mutations in a small proportion of
ASD cases. They are involved in various cellular processes such as transcriptional regula‐
tion, cell cycle regulation, genomic stability and DNA damage repair, but it is still unclear
how mutations in chromatin regulators lead to behavioral phenotypes. Following deletion
models,  it  is  suggested that  mutations that  affect  chromatin regulators can lead to ASD
because they are "global regulators" that are placed on top of a hierarchy of regulators. The
regulators interact with many genes and pathways, and thus disruption can simultaneous‐
ly affect multiple target genes. Furthermore, it is proposed that these genes may also act
as phenotypic capacitors, protecting processes of genetic development and environmental
perturbations [138].
Methylation of the genome in certain areas appears to remodel chromatin and consequently
the genes that are in this region. The regulation of each histone modification requires specific
enzymes that add or remove the methyl or acetyl group. Several mutated genes associated to
ASD encode histone demethylases, including KDM5C, a demethylase of histone H3K4
implicated in gene repression and JMJD1C, a demethylase of histone H3K9 implicated in
hormone-dependent transcriptional activation. Furthermore other genes involved in specific
chromatin remodeling, such as SMARCC1, SMARCC2, ARID1A, ARID1B, CHD8, CHD1,
CHD3, CHD75, and ATRX, have been described as mutated in rare cases [66, 77, 105, 114,
111]Lassalle, 2013).
10. Epigenetic: genomic imprinting, epimutations, histone and DNA
methylation
Epigenetic is a term used to refer to features of organisms, such as DNA and chromatin
modifications, that do not involve changes in DNA sequence. The effects of environment on
the phenotype are generally mediated through epigenetic mechanisms. These mechanisms,
such as DNA methylation, can become programmed (e.g. imprinted). Genomic imprinting is
a unique phenomenon wherein genes are expressed in a monoallelic way, and the choice of
which allele is expressed is determined by the parental origin of the allele. Disruptions of the
epigenome are called epimutations. Some of these appear to be corrected by normal germline-
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specific epigenetic reprogramming and are therefore not transmitted transgenerationally, but
others are not corrected and are transmitted over multiple subsequent generations [97].
Epigenetic mechanisms act on chromatin accessibility to transcriptional regulation. Then, they
regulate DNA structure and gene expression that can be influenced by exposure to environ‐
mental factors. The most studied are the methylation of genes and modification of histones.
Interestingly, epigenetic abnormalities are associated with several neurodevelopmental
diseases. The connection between ASD and epigenetic comes from the identification of genetic
mutations in imprinted regions and genes that control epigenetic processes. As cited before,
among the most common chromosomal alterations in ASD are duplications of the imprinted
region 15q11–13, which is maternally inheritable [96].
There are several possible explanations for the involvement of imprinted genes in autism. The
imprinted brain theory of autism suggests that autism is a disorder of the extreme imprinted
brain and would be caused by imbalances that involve increased effects of the ‘paternal brain’
relative to the ‘maternal brain’. Imprinting has been hypothesized to explain the gender
difference through the proposed action of unknown paternally imprinted loci on the X
chromosome. Also, as mentioned, autism has been strongly associated with chromosomal
abnormalities in the imprinted region of chromosome 15q. This includes the Angelman and
Prader-Willi syndromes, as well the 15q duplication syndrome, which occurs in up to 5% of
individuals with ASD. Imprinted genes may also contribute to autism indirectly as targets of
other genes such a regulatory connection between MECP2 (the gene associated with Rett
syndrome) and the imprinted gene UBE3A (associated with Angelman syndrome). Besides
this, imprinted genes are candidates for association with autism because of their functional
haploid state. This feature may make them extremely vulnerable to rare mutations because the
gene may be inactivated. Moreover, a single epigenetic change may lead to loss of imprinting,
leading to biallelic expression and to gene dysregulation (Ben-David, Shohat, Shifman, 2014).
Both genetic and environmental factors can affect the imprinting process and alter the level of
expression of genes. But the full contribution of genomic imprinting to the risk for autism is
still unclear.
The imprinted genes are expressed in several types of tissues but are highly expressed in the
brain. Human neurons require extensive methyl modifications throughout development and
postnatal life. Several important posttranslational modifications of histone core subunits
within nucleosomes involve methylation, an epigenetic mechanism. Recent unbiased genome-
wide analyses have turned up a multitude of novel candidate genes that encode nuclear factors
implicated in chromatin remodeling, histone demethylation, histone variants, and the
recognition of DNA methylation. Both histone and DNA methylation patterns are highly
dynamic processes in the early development phase that correlate with dynamic changes in cell
lineage and differentiation events. Interestingly, mutations in autism have been found in
several genes encoding proteins involved in demethylase reactions, that is, reactions that
remove methyl groups from histones or DNA (Lasalle, 2014).
The mechanism of action of the SHANK3 gene (also known as ProSAP2) is an example of this
phenomenon in ASD. The three members of the SHANK family, SHANK1, SHANK2 and
SHANK3 are expressed in different regions of the brain. SHANK3 is strongly reported to be
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involved in the etiology of autism since several mutations have been identified in a particular
phenotypic group of patients. SHANK3 regulates the structural organization of dendritic
spines and is a binding partner of NLS. It codes a synaptic scaffolding protein enriched in PSD
of excitatory synapses and plays important roles in the formation, maturation and maintenance
of synapses. Haploinsufficiency of this gene is related to the 22q13.3 deletion syndrome
(known as Phelan-McDermid syndrome), a developmental disorder which is characterized by
severe language and speech delay, hypotonia, global developmental delay and autistic
behavior. It is possible that loss of one copy of this gene makes the nervous system more
vulnerable to degeneration in the long term and less able to recover after psychiatric and
somatic events. Five CpG-islands have been identified in this gene, and tissue-specific
expression is epigenetically regulated by DNA methylation. Much evidence in animal models
has shown that SHANK3 variants are expressed in the developing rodent brain with expression
being regulated by DNA methylation of intragenic promoters [39, 147].
[75] reported that mothers of autistic children show significantly lower levels of methylfolate
and methionine, two essential precursors for methylation in DNA compared to a control group,
but methylation-inhibiting protein levels and S-adenosylmethionine (SAM), adenosine, and
homocysteine were elevated. SAM has a role in the DNA methyltransferase reaction, which
produces S-adenosylhomocysteine (SAH) and methylated DNA. The SAM/SAH ratio is
considered to be an indicator of DNA methylation potential.
Additionally,  oxidative stress in brain cells  caused by environmental and genetic factors
leads to decreased activity of the methionine synthase enzyme which participates in DNA
methylation processes. When the activity of this enzyme is impaired, affected individuals
can exhibit attention deficits and other signs, including autistic behavior symptoms due to
defects  in  the  expression  of  genes  controlled  by  this  epigenetic  mechanism  [42,  104].
Therefore, environmental factors may also activate intracellular pathways during embryon‐
ic  development,  causing  epigenetic  changes  in  neural  function  that  would  explain  the
relationship between environmental signals and the genome in the regulation of individu‐
al differences in behavior [166].
A study in Sweden with 208 autistic children showed an association between advanced
paternal age and an increasing risk for ASD in offspring. Autistic-like traits in the normal
population are associated to both young and advancing paternal age and the autistic similarity
in twins seems to increase with advancing paternal age. Exposure to toxic agents during life,
de novo mutations in germ lines and epigenetic alterations are correlated factors [72, 90].
Advancing age in mothers has also been reported as a risk factor for ASD [116].
Thus, epigenetic alterations may be the biological targets through which environmental factors
can cause autism. Imprinted genes may be associated with autism because they are involved
in brain development and also because they may be more vulnerable to genetic or epigenetic
mutations. Some features of ASD are highly consistent with epigenetic dysregulation such as
the discordance between monozygotic twins, parental origin and the gender-dependent effects
of some alterations. The cause of autism is not just by congenital genetic defects but can also
be caused by environmental factors via epigenetic factors, with epigenetic modifications being
affected by environmental factors including fetal exposure to drugs.




11.1. Toxicity during neurodevelopment
Although the involvement of genetic alterations in ASD is clearly accepted, new studies point
to a similar or even greater contribution by environmental factors, particularly environmental
toxicants. Toxic chemicals cause dysregulation of the developing human brain by interacting
with the genome or through direct toxicity.
The developing human brain is exceptionally sensitive to injury caused by toxic chemical
exposure with several developmental processes being highly vulnerable. The dissemination
of chemical industrial agents in the environment is important contributor to the call “global
silent pandemic of neurodevelopmental toxicity” [63]. An estimative by U.S. National
Academy of Sciences (NAS) shows that 3% of all neurobehavioral disorders including ASD,
attention-deficit hyperactivity disorder and dyslexia are caused directly by exposure to
environmental toxics and that another 25% are caused by interactions between environmental
factors and inherited susceptibility [103].
About 80,000 new synthetic chemicals have been developed in the past 50 years, but only about
20% was screened for potential toxicity in early neurodevelopment. The human fetus is
susceptible and not well protected against industrial chemicals, because the placenta does not
block the passage of all toxicants from the maternal to fetal circulation. The individual’s brain
is unique and individual variability in genetic susceptibility can influence responses to
environmental toxicants [62, 79, 106].
Exposure to many environmental toxicants has been correlated to autism including pesticides,
polychlorinated biphenyls, solvents, toluene, toxic waste, and heavy metals such as mercury,
lead and arsenic, besides exposure to automotive air pollution [115, 132, 152]. On the other
hand, there was a false indicative association between these disorders and vaccines such as
the measles, mumps, rubella vaccine and thimerosal-containing vaccines against diphtheria,
tetanus and pertussis vaccine. One meta-analysis, combining the results of five previous
studies involving 1,256,407 children with five case-controlled studies with a further 9,920
children show that there was no relationship between vaccination and autism [144].
There is thus strong evidence that the relation between environmental and genetic factors may
converge to neurotoxic mechanisms that could lead to behavior disorders. But what kind of
biological mechanisms would be involved in the causation of autism due to toxic agents?
Epigenetic mechanisms are known to affect the subsequent gene expression in the brain as has
already been described in this chapter. Toxics can lead to a modification in epigenetic gene
expression, resulting in methylation, histone modification or changes in non-protein-coding
RNA [60]. However, possible individual susceptibilities to toxicants implicated in ASD,
including altered detoxification, genetic factors, oxidative stress, altered neuronal develop‐
ment, epigenetic mechanisms, synaptic function, hormonal factors, etc., may amplify the
effects of toxicants during the prenatal and early postnatal periods [123]. The susceptibility to
effects of environmental toxicants needs more attention and studies.
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11.2. Oxidative stress
ASD also can be characterized by some physiological abnormalities, such as oxidative stress
and immune dysregulation/inflammation. Many of the behavioral and cognitive features of
ASD appear to arise from dysfunctions of the brain but studies have documented physiological
abnormalities in organs other than the brain [122].
Many studies have reported genetic variations in glutathione-related pathways associated
with autism, such as lower concentrations of reduced glutathione (GSH), higher levels of
oxidized glutathione (GSSG) and a decrease in the GSH/GSSG redox ratio, along with a lower
mitochondrial GSH reserve in individuals with ASD compared to controls [19, 2952, 65, 75 ,
121]. Moreover, ASD severity has been correlated with lower GSH levels and markers of
increased oxidative stress [2, 56, 123]. Oxidative stress studied in postmortem brain samples
from individuals with ASD demonstrated low levels of GSH, the major cellular antioxidant,
oxidative damage to proteins, lipids and deoxyribonucleic acid (DNA) as well as alterations
in the activity of enzymes important for redox metabolism [123, 142].
Adaptive responses to oxidative stress were shown by [102], when significantly lower
methionine synthase mRNA levels and lower homocysteine and cystathionine concentrations
were observed in the frontal cortex of the brains of ten individuals with autism compared to
ten controls.
Also it is possible that the reduced transportation of folate into the brain as a consequence of
the folate receptor alpha autoantibody or mitochondrial dysfunction could reduce the
methylation process and glutathione metabolism. Many findings reported for the brain
(oxidative damage to lipids, protein and DNA, glutathione abnormalities and reduced
function of enzymes essential in oxidative stress regulation) have been found in the blood,
immune cells and cell lines from individuals with ASD, raising the question of whether these
findings are specific to the brain or whether they represent a more general process (Frye et al.,
2013; [123].
11.3. Immune system
Dysfunctional immune activity, both innate and adaptive, can impact neurodevelopment,
cognitive function and behavior, suggesting a profound effect on neurodevelopment. Some
studies in individuals with ASD have reported evidence of immune dysregulation and
inflammation related to ASD, including disruption of genes of the immune system with
elevations of tumor necrosis factor-alpha (TNF-α) in lymphocytes and amniotic fluid, altera‐
tions of immune proteins, and increased levels of cytokines, expression in genes related to
immunity and microglial cell activation in brain tissue [113]. The expression of inflammatory
genes in brain tissue was studied by [163], who reported that nuclear factor-kappa β expression
in the orbitofrontal cortex was increased in individuals with autism compared to controls.
Microglias, a type of glial cell, are the resident macrophages of the brain and spinal cord. They
therefore act as the first and main line of active immune defense of the CNS and participate in
immune surveillance of the CNS and synaptic pruning in normal neurodevelopment. They
are activated to eliminate some agents and damaged cells via phagocytosis, but, they may
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increase inflammation if chronically activated by releasing proinflammatory cytokines and
free radicals [41]. Changes in microglial morphology and gene expression are seen in many
psychiatric disorders and neurodegenerative diseases, such as Alzheimer’s, Parkinson’s,
Multiple Sclerosis and autism. [100] and [165] reported that microglias in the dorsolateral
prefrontal cortex were frequently located closer to neurons in ASD individuals compared to
controls. Another study with autism showed microglial activation in the cerebellum, brain‐
stem, corpus callosum, fusiform gyri, superior temporal gyri, anterior cingulate, orbitofrontal,
and parietal lobes [139].
Proteomic analysis indicates that the levels of many immune proteins in plasma, such as
cytokines, chemokines, complement proteins, adhesion molecules and growth factors are
altered in ASD [113]. Increases in plasma levels of pro-inflammatory cytokines [interleukin
(IL)-1β, IL-6, IL-8 and IL-12p40] as well as macrophage migration inhibitory factor (MIF) and
platelet-derived growth factor (PDGF), have been reported in ASD [11, 64].
Alterations in immune mediators can occur at an early stage of development and might alter
NMDA and NMD receptor-mediated excitatory synaptic transmission and plasticity, which
is relevant to ASD (Escobar et al., 2011). These immune mediators may be related in LTP which
is involved in synaptic plasticity in learning and memory processes. IL-1 influences many
molecular components of LTP, such as NMDA and AMPA receptor signaling and glutamate
release. IL-6 is involved in the generation of LTP and an increase in IL-6 leads to a reduction
of insulin-like growth factor (IGF)-binding protein 3 and IGF1 [43, 117]. Furthermore, other
cytokines, such as IL-18, IL-1b, and TNF-α, act on AMPA and NMDA receptors in different
ways [25].
Increases of pro-inflammatory cytokines (including TNF-α, IL-6 and granulocyte-macrophage
colony-stimulating factor), a T helper cell type 1 cytokine (interferon gamma) and a chemokine
(IL-8) were reported in postmortem frontal cortex brain samples of autistic individuals, but no
significant differences in T helper cell type 2 cytokines were identified (IL-4, IL-5, and IL-10)
[86]. The cytokines IL-2 and IL-4 have been shown to influence repetitive and cognitive
behaviors. Mice treated with IL-2 showed an increased “climbing behavior” that is thought to
denote repetitive behavior, a pattern of behavior that is characteristic of ASD.
There is evidence suggesting a role of immune dysfunction in ASD symptoms, but further
investigations should be carried out to clarify these findings because it is still unknown
whether these changes are a primary cause or a secondary consequence of neuronal deficits.
11.4. Microbiota and autism
Gastrointestinal (GI) disorders are a comorbidity of autism and interestingly have a strong
correlation with disease severity [7, 16]. Thus, a growing number of papers point to the
importance of the so-called "brain-gut axis", revealing the central role of the intestinal micro‐
biota (the new name of "microflora") in postnatal development and maturation of the immune
and endocrine systems for control signaling in the CNS, brain function, and behavior [51; 158].
Individuals with ASD often suffer from GI illnesses, e.g., diarrhea, constipation, bloating, and
gastroesophageal reflux [22, 3]. The composition of the microbiota is influenced primarily by
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genetic factors, age and diet [80, 168], although the interactions between these are multifactorial
and not well defined yet [21].
Thus, several studies have been conducted in an attempt to profile the microbiota in ASD
compared with healthy siblings and controls [4, 51, 59]. While some authors have reported
little or no differences in the composition of the intestinal flora between children with ASD
and their unaffected siblings, the imbalance in the intestinal microbial composition in samples
of ASD has been identified, especially when compared to controls [49, 50].
Analyses of the feces of patients with ASD have revealed that the microbiome of ASD is
significantly different to controls and consists in over 1,000 different species compared to
unaffected children. Of the phyla, patients with autism have underrepresented Firmicutes and
actinobacteria, especially bifidobacteria, and over-represented Bacteroidetes and proteobacteria
compared to control individuals [49, 51, 119].
Interestingly, non-autistic siblings often presented intermediate microbiota profiles between
ASD and controls [49, 155], possibly due to genetic factors, but also as a reflection of shared
environmental conditions. These studies are complicated by the fact that autistic individuals
often receive medications such as antibiotics and are often on special diets or have repetitive
eating habits, both of which can alter the composition of the microbiota [89].
Interestingly, although Bacteroidetes are over-represented in ASD feces, the presence of the
genus Prevotella and other fermenters, albeit in lesser amounts, has been described in the gut
of children with ASD. Prevotella do not only have the ability to synthesize vitamin B1, which
attenuates the ASD symptoms, but it is also considered a central niche to maintain the structure
of the intestinal microbial community of healthy humans [10, 13, 162]. Moreover, Propionibac‐
terium and Clostridium that are over-represented in the intestine of ASD, produce propionic
acid, a short-chain fatty acid capable of passing the gut-blood-brain barrier thereby changing
neurophysiological processes by binding to acetyl-CoA and acetyl-carnitine which are
involved in mitochondrial lipid transport. Recent experiments have shown that administration
of propionic acid in young mice causes mental retardation with cognitive disabilities, innate
neuroinflammatory response and restricted, repetitive behavioral, symptoms consistent with
autism [53, 92]. Propionic acid induces behavioral and functional alterations in the brain of
animals. Most likely, the presence of this acid alters mitochondrial function. Taken together,
these reports support a view that the metabolism of proteins and the host/pathogen relation‐
ship is altered in patients with autism [99].
Few studies have considered a deregulated metabolism of fecal levels free of amino acids
in autism. Certain amino acids, in particular glutamic acid (Glu), act as neurotransmitters
in  the  center  of  the  CNS.  An excess  of  Glu  leads  to  neuronal  cell  death  and  plays  an
important  role  in  the  pathophysiology of  several  neuropsychiatric  disorders  [127].  High
levels of Glu were found in fecal samples of autistic children [37]. As it has a role in brain
development, the findings support the hypothesis that glutamatergic neurotransmission is
involved in ASD [130].
The microbiota might also be involved in the etiology of the disease via interactions with
the immune system. Some of the possible mechanisms described above are likely to involve
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changes  in  the  global  balance  of  the  entire  microbial  community,  while  others  may  be
exercised by certain bacteria. More studies are needed to clarify whether the gut microbio‐
ta in fact plays a role in ASD. These include prospective studies to address the issue of
cause and consequence, and intervention studies aimed at modulating the microbiota with
probiotics  or  dietary  interventions.  The  right  profile,  the  categorization  of  patients  and
control groups, with the application of molecular techniques to verify the profile of fecal
microbiota and urinary metabolome will corroborate the underlying relationship between
gut microbes and the host [34].
Some authors believe that the action of microbiota may have much wider effects on the
physiology of the host than originally thought, and emerging evidence shows that it may
include modulation of brain activity and behavior. Differences in the composition of the
microbiota between individuals with ASD and healthy controls were identified in several
studies, both based on bacterial cultures and on molecular methods [18]. However, changes
in bacterial diversity that were reported in one study [51] were not confirmed by another [158].
The direct comparison between studies is complicated because different methodologies are
employed and study groups may not be directly comparable due to the heterogeneous nature
of ASD [89]. However, if the differences in gut microbiota between autistic children and
controls are one of the causes of the disorder or the result, could have implications on the
diagnosis, treatment and prevention [37].
Nevertheless, despite the substantial amount of data, it is not possible to clarify whether the
results represent the presence of a causative agent, or reflect a consequence of treatment, or
whether they are nothing more than confounders. This has to be considered and caution is
needed before recommending "miracle diets" to the child and family that may only increase
the anxiety in respect to symptom improvement.
12. Etiology and mechanisms of sexual differences
It is well known that ASD affects more males at a ratio of 4 boys:1 girl. Some studies suggest
that gender differences in phenotypic presentation, including less severe manifestations of
restricted and repetitive behaviors in girls, seem to affect this ratio. Genetic studies show that
girls seem to be more "protected" from the effects of inherited and de novo variants that cause
ASD than boys. This suggests that genes that participate in sexual development and/or sex
hormones, particularly testosterone, may modulate the effects of genetic variations in the
autistic phenotype [157].
Despite the fact that ASD is more prevalent in boys de novo mutations are also more frequent
in girls with ASD. The female protection theory fits in with the model of loss of robustness.
According to this model, besides the variations between individuals, there is a difference in
the average degree of robustness of the brain between males and females. According to this
hypothesis the development of the female brain is more robust, and this may explain the higher
rate of severity of behaviors when de novo mutations are present in girls with ASD. The brain
can also be more vulnerable compared to other organs because it is a complex organ that
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develops later in life and is mainly composed of terminally differentiated cells. In the first year
of life, the brain may be particularly sensitive to reduced robustness because social develop‐
ment depends on signals from the environment [138].
Although neurodevelopmental systems evolved to be robust, they can be vulnerable to
disturbances in a specific subset of genes called phenotypic capacitors [85]. Phenotypic
capacitors are genes that act against disturbances and thus contribute to the robustness of the
phenotype. Thus, phenotypic capacitors, when operating normally, can prevent the develop‐
ment of diseases such as ASD, even in patients exposed to genetic and environmental risks.
This means that girls are less likely to develop ASD, but when they have, they tend to have a
more severe phenotype [138].
There seems to be unknown factors that "protect" females from ASD [157]. Recent genome
studies showed that, on average, women with ASD have more mutations than men, including
single nucleotide variants (SNVs) and CNVs [74, 84, 105]. Furthermore, de novo CNVs in
females were larger and included significantly more genes than males [84].
Moreover, not all genes in the inactive X chromosome are inactivated, and the genes that escape
X inactivation in females are revealing some interesting insights into gender differences related
to chromatin. KDM5C and JARID1C are genes that escape X chromosome inactivation (Xu,
Deng, Disteche, 2008). In addition, the gene encoding O-linked N-acetylglucosamine (O-
GlcNAc) transferase (OGT) which regulates chromatin remodeling factors is less expressed in
males than in females and the expression is reduced further by prenatal stress [70]. These sexual
and epigenetic differences must be investigated further in respect to the protective effect of
the female gender in autism [81].
Recently, gender-specific gene expression obtained from the transcriptome of normal human
brain development using a bioinformatics approach suggested that male-biased genes are
enriched for the processes of extracellular matrix formation/glycoproteins, immune response,
chromatin, and cell cytoskeleton. These pathways have been repeatedly implicated in autism
and demonstrate that autism candidate genes are also enriched for these pathways. Further‐
more, the development of the male brain may be naturally more susceptible to environmental
factors as its normal development is more strictly dependent on the immune system [167].
A gender-dependent difference in the incidence of neural tube defects has been described. It
was speculated that these defects are due to a synergistic effect between the gene expression
of SOX9 and Barx1. SOX9 is an essential transcription factor for skeletal development, but it
is also involved in the development of the male phenotype (Barriounuevo & Scherer, 2010),
thus contributing to the increased risk of autism in males. Interestingly, a study showed up-
regulation of SOX9 in autism [55].
On the other hand, altered behaviors in ASD are often related to a “more masculine” pattern
of behavior linked to testosterone. However, although current levels of steroid hormones
appear to be altered in patients with autism, the data indicate that prenatal testosterone by
itself does not seem to be sufficient for the disorder to develop [125].
Differences between individuals with an atypical karyotype (monosomy X or Y or X-polyso‐
my) and those with a typical karyotype are often interpreted as being significant for the
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difference in susceptibility between genders. However, it is likely that many of the differences
arise because of hyperexpression or hypoexpression of genes in pseudo autosomal regions that
escape X inactivation, thereby being similarly expressed in men and women with a typical
karyotype. The addition or loss of an X or Y chromosome, which leads to altered protein levels
that are atypical or typical for both men and women, cannot explain the gender difference in
ASD. However, some genes on the X chromosome are not in these regions and have no
corresponding functional alleles on the Y chromosome, and escape X inactivation in some
circumstances [125].
Moreover, the SRY gene is mapped in a region on the Y chromosome and can also directly
regulate the gene monoamine oxidase A (MAOA) that is located in the Xp11.3 region and
encodes a key enzyme in the breakdown of catecholamines and other monoamines. SRY can
directly affect transcription in the brain [159]. As individuals diagnosed with ASD are found
with changes in catecholamine and metabolite levels in the dependent activity MAO-A and
autism severity is associated with child and maternal MAO-A genotypes, the disruption of the
synthesis of catecholamines may be modulated by the gender-specific SRY gene associated
with ASD. Several genes on the Y chromosome are expressed in the brain. Since this leads to
a specific expression of gender in the brain, these genes, some of which play a role in catecho‐
laminergic functions, are candidate genes for the increased susceptibility to ASD in males. An
investigation of the role of these genes will possibly clarify the gender-specific mechanisms
underlying ASD and thus help in the understanding of the etiology of ASD [31, 125].
Another factor that may contribute to the skewed gender ratio in ASD is parental age. Increased
parental age is known to increase the risk of a child with ASD [45] and there are some
indications that parental age affects the gender ratio of children diagnosed with ASD [125].
The male-female ratio dropped from 6.2:1 in under 30-year-old parents to 1.2:1 in parents older
than 44 years old [8]. This finding may be related to the higher frequency of de novo mutations
which are more common in older men and seem to play a minor role in the gender bias in the
incidence of familial ASD. However, it is still not clear whether this effect is true for simplex
families, which are most representative of ASD in the general population [125].
13. Conclusion
Thus, considering all that has been studied about ASD, it is difficult to conduct a comprehen‐
sive analysis about the etiologic complexity, without running the risk of over or under
estimating some factors. On consulting the available literature on ASD, there is an impression
that all can cause autism. The truth is that everything that affects the CNS system can interfere
with mental health and this opens up a universe of possibilities. The gene expression, immune
susceptibility and environmental stressors, even those that affect men more than women, need
to be organized using a multidisciplinary approach in order to explain what actually happens
in normal CNS development within the first three years of life. From there, the goal is to have
a method of comprehensively analyzing each particular case to try to obtain specific treatment.
While this is not available, it is interesting to investigate the most common risk factors and
give support to the patients and families in order to improve their quality of life.
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